News
FWBI
2.730
-9.60%
-0.290
Weekly Report: what happened at FWBI last week (0415-0419)?
Weekly Report · 3d ago
BTTR, ICCM and SXTC among pre-market losers
Seeking Alpha · 04/17 12:21
Weekly Report: what happened at FWBI last week (0408-0412)?
Weekly Report · 04/15 09:33
Weekly Report: what happened at FWBI last week (0401-0405)?
Weekly Report · 04/08 09:35
Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now
NASDAQ · 04/05 13:55
First Wave BioPharma Inc reports results for the quarter ended in December - Earnings Summary
First Wave BioPharma Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $5.35 per share. Reported revenue was zero; analysts expected zero. First Wave Biopharma Inc shares have gained 4.3% so far this year.
Reuters · 04/01 21:01
Weekly Report: what happened at FWBI last week (0325-0329)?
Weekly Report · 04/01 09:35
First Wave Bio Inc. Grapples with Uncertainty in Pending Niclosamide Deal
First Wave Bio Inc. Faces significant uncertainty regarding the completion of the Niclosamide Sale. The average FWBI stock price target is $36.00, implying 721.92% upside potential. The company has disclosed a new risk, in the Supply Chain category.
TipRanks · 03/31 06:02
First Wave BioPharma Inc <FWBI.OQ> expected to post a loss of $4.03 a share - Earnings Preview
First Wave BioPharma Inc expected to post a loss of $4.03 a share - Earnings Preview. The company is expected to show change in quarterly revenue when it reports results on April 1. Average analyst estimate for first wave biopharma's quarterly revenue is $1.7 million.
Reuters · 03/29 20:06
First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 03/27 16:00
HC Wainwright & Co. Reinstates Neutral on First Wave BioPharma
Benzinga · 03/25 10:44
Weekly Report: what happened at FWBI last week (0318-0322)?
Weekly Report · 03/25 09:36
First Wave Biopharma Inc: Current report
Press release · 03/22 22:21
First Wave BioPharma Inc <FWBI.OQ> expected to post a loss of $4.66 a share - Earnings Preview
First Wave BioPharma Inc expected to post a loss of $4.66 a share - Earnings Preview. The one available analyst rating on the shares is "buy" - Wall Street's median 12-month price target for the company is $36.00.
Reuters · 03/22 20:49
First Wave BioPharma Inc <FWBI.OQ> expected to post a loss of $4.66 a share - Earnings Preview
First Wave BioPharma Inc expected to post a loss of $4.66 a share - Earnings Preview. The one available analyst rating on the shares is "buy" - Wall Street's median 12-month price target for the company is $36.00.
Reuters · 03/19 21:27
Weekly Report: what happened at FWBI last week (0311-0315)?
Weekly Report · 03/18 09:35
First Wave BioPharma Is Maintained at Buy by Roth MKM
Dow Jones · 03/15 14:00
First Wave BioPharma Price Target Cut to $36.00/Share From $40.00 by Roth MKM
Dow Jones · 03/15 14:00
Roth MKM Maintains Buy on First Wave BioPharma, Lowers Price Target to $36
Benzinga · 03/15 13:49
12 Health Care Stocks Moving In Friday's Pre-Market Session
Better Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. Madrigal Pharmaceuticals shares moved upwards by 22.34%. Akebia Therapeutic and Rallybio both reported better than expected Q4 earnings.
Benzinga · 03/15 13:06
More
Webull provides a variety of real-time FWBI stock news. You can receive the latest news about First Wave Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About FWBI
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.